Literature DB >> 34950346

Hemodynamic Management of Patients with Ejection Fraction < 50% Undergoing Pulmonary Vein Ablation.

Aaron B Hesselson1, Heather Hesselson2.   

Abstract

There is no consensus regarding optimal methodology forblood pressure monitoring inpatients with a depressed ejection fraction undergoingcatheter ablationfor atrial fibrillation. Our goalswere to determine ifhemodynamicmanagementdifferences exist during radiofrequency ablation for atrial fibrillation in patients with and without an ejection fraction< 50%, and whether management was influenced by the utilization of invasive arterial blood pressure monitoring. This single-center trial retrospectively compared blood pressure management during catheterablation of atrial fibrillationin all patients with an ejection fraction< 50% over a 2-year span (n=44), and compared to an age-matched cohort with preserved ejection fraction ablated over the same span in time (n=44). Blood pressure was not significantly managed differently between the groups, and did not appear to be influenced by the use of invasive arterial blood pressure monitoring.Hemodynamic management is similar across the spectrum of ejection fraction, regardless of invasive arterial blood pressure monitoring, which challenges the need for invasive arterial blood pressure monitoringduringcatheter ablation ofatrial fibrillationin left ventricular systolic dysfunction.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Left ventricular systolic dysfunction; Tolerance

Year:  2021        PMID: 34950346      PMCID: PMC8691288          DOI: 10.4022/jafib.20200439

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  22 in total

1.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Authors:  Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane
Journal:  Heart Rhythm       Date:  2017-05-12       Impact factor: 6.343

2.  Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial.

Authors:  Michael R MacDonald; Derek T Connelly; Nathaniel M Hawkins; Tracey Steedman; John Payne; Morag Shaw; Martin Denvir; Sai Bhagra; Sandy Small; William Martin; John J V McMurray; Mark C Petrie
Journal:  Heart       Date:  2010-11-04       Impact factor: 5.994

3.  The effect of propofol on haemodynamics: cardiac output, venous return, mean systemic filling pressure, and vascular resistances.

Authors:  F de Wit; A L van Vliet; R B de Wilde; J R Jansen; J Vuyk; L P Aarts; E de Jonge; D P Veelo; B F Geerts
Journal:  Br J Anaesth       Date:  2016-06       Impact factor: 9.166

4.  Heart Failure with Mid-Range Ejection Fraction - a New Category of Heart Failure or Still a Gray Zone.

Authors:  Anca Andreea Andronic; Sorina Mihaila; Mircea Cinteza
Journal:  Maedica (Bucur)       Date:  2016-12

Review 5.  Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction.

Authors:  Atul Verma; Jonathan M Kalman; David J Callans
Journal:  Circulation       Date:  2017-04-18       Impact factor: 29.690

6.  Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.

Authors:  Robby Nieuwlaat; Luc W Eurlings; John G Cleland; Stuart M Cobbe; Panos E Vardas; Alessandro Capucci; José L López-Sendòn; Joan G Meeder; Yigal M Pinto; Harry J G M Crijns
Journal:  J Am Coll Cardiol       Date:  2009-05-05       Impact factor: 24.094

7.  In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures.

Authors:  Abhishek Deshmukh; Nileshkumar J Patel; Sadip Pant; Neeraj Shah; Ankit Chothani; Kathan Mehta; Peeyush Grover; Vikas Singh; Srikanth Vallurupalli; Ghanshyambhai T Savani; Apurva Badheka; Tushar Tuliani; Kaustubh Dabhadkar; George Dibu; Y Madhu Reddy; Asif Sewani; Marcin Kowalski; Raul Mitrani; Hakan Paydak; Juan F Viles-Gonzalez
Journal:  Circulation       Date:  2013-09-23       Impact factor: 29.690

8.  A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.

Authors:  David G Jones; Shouvik K Haldar; Wajid Hussain; Rakesh Sharma; Darrel P Francis; Shelley L Rahman-Haley; Theresa A McDonagh; S Richard Underwood; Vias Markides; Tom Wong
Journal:  J Am Coll Cardiol       Date:  2013-03-07       Impact factor: 24.094

Review 9.  Heart-lung interactions during mechanical ventilation: the basics.

Authors:  Syed S Mahmood; Michael R Pinsky
Journal:  Ann Transl Med       Date:  2018-09

10.  Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.

Authors:  Douglas L Packer; Daniel B Mark; Richard A Robb; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Peter A Noseworthy; Yves D Rosenberg; Neal Jeffries; L Brent Mitchell; Greg C Flaker; Evgeny Pokushalov; Alexander Romanov; T Jared Bunch; Georg Noelker; Andrey Ardashev; Amiran Revishvili; David J Wilber; Riccardo Cappato; Karl-Heinz Kuck; Gerhard Hindricks; D Wyn Davies; Peter R Kowey; Gerald V Naccarelli; James A Reiffel; Jonathan P Piccini; Adam P Silverstein; Hussein R Al-Khalidi; Kerry L Lee
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.